# Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

> **NCT00796510** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 3 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Hypertension

## Interventions

- **DRUG:** Sitaxsentan
- **DRUG:** Sitaxsentan and Sildenafil

## Key facts

- **NCT ID:** NCT00796510
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796510, "Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00796510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*